Fe3O4-Lipid Nanoparticles as Inorganic-Organic Hybrid Nano-Carriers for Evaluation of Paclitaxel Delivery to Treat Breast Cancer
نویسندگان
1 Fergana medical institute of public health, Fergana, Uzbekistan
2 Tashkent State Medical University, Tashkent, Uzbekistan
3 Samarkand State Medical University, 140100 Samarkand, Uzbekistan
4 Bukhara State University, Bukhara, Uzbekistan
5 Tashkent State Technical University named after Islam Karimov, Republic of Uzbekistan
6 Urgench State Pedagogical Institute, Uzbekistan
7 Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan
8 Zarmed University, Samarkand, Republic of Uzbekistan
9 Andijan State Medical Institute, Andijan, Uzbekistan
10 Fergana medical institute of public health, Fergana, Uzbekistan
11 Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan
12 Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan
13 Urgench State University, Urgench, Uzbekistan
doi
10.22052/JNS.2026.01.073چکیده
The strategic convergence of inorganic magnetism with organic lipid biology offers a compelling route to improve chemotherapeutic delivery for breast cancer. Here, we report Fe3O4-lipid hybrid nanoparticles (Fe3O4-LNP) as inorganic–organic nanocarriers for paclitaxel (PTX) with enhanced loading, controlled release, and magnetically guided tumor targeting. Fe3O4 cores (≈15 nm) were synthesized via alkaline co-precipitation and encapsulated within a DSPC/cholesterol lipid bilayer by a thin-film hydration–extrusion method, enabling a core–shell architecture that preserves superparamagnetism (Ms ≈ 68 emu g−1 for bare cores; ≈42 emu g−1 for hybrids) while adding a lipid corona that promotes biocompatibility and cargo loading. PTX was incorporated during film formation, yielding encapsulation efficiencies (EE) around 89–91% and a drug loading capacity of ~8% (w/w) across three batches. In vitro release demonstrated a biphasic profile with initial burst followed by sustained release, more pronounced under acidic conditions (pH 5.0) than physiologic pH (7.4), indicating tumor-responsive delivery. Cytotoxicity assays against MCF-7 and MDA-MB-231 cells revealed superior potency for Fe3O4-LNP/PTX relative to free PTX and Cremophor EL formulations, with IC50 values reduced by factors of 2–2.2. Cellular uptake studies (DiI labeling) showed robust internalization and pronounced magnetically enhanced accumulation (3.4-fold in magnetized regions), validating magneatic guidance as a means to boost tumor localization. Collectively, Fe3O4-LNP/PTX constitutes a promising theranostic platform with favorable drug-loading, controllable release, strong anti-tumor activity, and magnetic targeting potential, acknowledging translational challenges and outlining future in vivo evaluation.
